Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines

Elizabeth A. Griffiths; Vivek Roy; Laura Alwan; Kimo Bachiashvili; John Baird; Rita Cool; Shira Dinner; Mark Geyer; John Glaspy; Ivana Gojo; Ashley Hicks; Avyakta Kallam; Wajih Zaheer Kidwai; Dwight D. Kloth; Eric H. Kraut; Daniel Landsburg; Gary H. Lyman; Anjlee Mahajan; Ryan Miller; Victoria Nachar; Seema Patel; Shiven Patel; Lia E. Perez; Adam Poust; Fauzia Riaz; Rachel Rosovsky; Hope S. Rugo; Shayna Simon; Sumithira Vasu; Martha Wadleigh; Kelly Westbrook; Peter Westervelt; Ryan A. Berardi; Lenora Pluchino

doi:10.6004/jnccn.2022.0026

Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines

Elizabeth A. Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, Mark Geyer, John Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Anjlee Mahajan, Ryan Miller, Victoria NacharSeema Patel, Shiven Patel, Lia E. Perez, Adam Poust, Fauzia Riaz, Rachel Rosovsky, Hope S. Rugo, Shayna Simon, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Ryan A. Berardi, Lenora Pluchino

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapyinduced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

Original language	English (US)
Pages (from-to)	436-442
Number of pages	7
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2022.0026
State	Published - May 2022

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2022.0026

Cite this

Griffiths, E. A., Roy, V., Alwan, L., Bachiashvili, K., Baird, J., Cool, R., Dinner, S., Geyer, M., Glaspy, J., Gojo, I., Hicks, A., Kallam, A., Kidwai, W. Z., Kloth, D. D., Kraut, E. H., Landsburg, D., Lyman, G. H., Mahajan, A., Miller, R., ... Pluchino, L. (2022). Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 20(5), 436-442. https://doi.org/10.6004/jnccn.2022.0026

@article{e759582367314532a1c896758bdf9339,

title = "Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapyinduced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.",

author = "Griffiths, {Elizabeth A.} and Vivek Roy and Laura Alwan and Kimo Bachiashvili and John Baird and Rita Cool and Shira Dinner and Mark Geyer and John Glaspy and Ivana Gojo and Ashley Hicks and Avyakta Kallam and Kidwai, {Wajih Zaheer} and Kloth, {Dwight D.} and Kraut, {Eric H.} and Daniel Landsburg and Lyman, {Gary H.} and Anjlee Mahajan and Ryan Miller and Victoria Nachar and Seema Patel and Shiven Patel and Perez, {Lia E.} and Adam Poust and Fauzia Riaz and Rachel Rosovsky and Rugo, {Hope S.} and Shayna Simon and Sumithira Vasu and Martha Wadleigh and Kelly Westbrook and Peter Westervelt and Berardi, {Ryan A.} and Lenora Pluchino",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2022.",

year = "2022",

month = may,

doi = "10.6004/jnccn.2022.0026",

language = "English (US)",

volume = "20",

pages = "436--442",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

Griffiths, EA, Roy, V, Alwan, L, Bachiashvili, K, Baird, J, Cool, R, Dinner, S, Geyer, M, Glaspy, J, Gojo, I, Hicks, A, Kallam, A, Kidwai, WZ, Kloth, DD, Kraut, EH, Landsburg, D, Lyman, GH, Mahajan, A, Miller, R, Nachar, V, Patel, S, Patel, S, Perez, LE, Poust, A, Riaz, F, Rosovsky, R, Rugo, HS, Simon, S, Vasu, S, Wadleigh, M, Westbrook, K, Westervelt, P, Berardi, RA & Pluchino, L 2022, 'Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 5, pp. 436-442. https://doi.org/10.6004/jnccn.2022.0026

TY - JOUR

T1 - Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines

AU - Griffiths, Elizabeth A.

AU - Roy, Vivek

AU - Alwan, Laura

AU - Bachiashvili, Kimo

AU - Baird, John

AU - Cool, Rita

AU - Dinner, Shira

AU - Geyer, Mark

AU - Glaspy, John

AU - Gojo, Ivana

AU - Hicks, Ashley

AU - Kallam, Avyakta

AU - Kidwai, Wajih Zaheer

AU - Kloth, Dwight D.

AU - Kraut, Eric H.

AU - Landsburg, Daniel

AU - Lyman, Gary H.

AU - Mahajan, Anjlee

AU - Miller, Ryan

AU - Nachar, Victoria

AU - Patel, Seema

AU - Patel, Shiven

AU - Perez, Lia E.

AU - Poust, Adam

AU - Riaz, Fauzia

AU - Rosovsky, Rachel

AU - Rugo, Hope S.

AU - Simon, Shayna

AU - Vasu, Sumithira

AU - Wadleigh, Martha

AU - Westbrook, Kelly

AU - Westervelt, Peter

AU - Berardi, Ryan A.

AU - Pluchino, Lenora

PY - 2022/5

Y1 - 2022/5

N2 - The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapyinduced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

AB - The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapyinduced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

UR - http://www.scopus.com/inward/record.url?scp=85129961219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129961219&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0026

DO - 10.6004/jnccn.2022.0026

M3 - Article

C2 - 35545171

AN - SCOPUS:85129961219

SN - 1540-1405

VL - 20

SP - 436

EP - 442

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this